Inclusion Criteria:  Provision of signed and dated informed consent form (ICF) Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an investigator  Exclusion Criteria:  Female who is pregnant or lactating Presence or history of significant gastrointestinal, metabolic, liver or kidney disease, or surgery that may affect drug bioavailability (excluding appendectomy and cholecystectomy) History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease Have a history of a malignancy (or active malignancy), with the exception of treated basal cell or squamous cell carcinoma Use of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) within 14 days prior to or use of any over-the-counter drugs in the 7 days prior to the first study drug administration Positive urine alcohol test result and/or drugs of abuse at Screening or prior to the first drug administration (including cotinine, cannabinoids, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines) Positive test results for HIV-1/HIV-2 Antibodies, Hepatitis B surface Antigen (HBsAg) or Hepatitis C Antibody (HCVAb) Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to Screening Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening Plasma donation within 7 days prior to screening